Bioxytran Earnings Call Transcripts
Fiscal Year 2026
-
A novel antiviral based on polysaccharide galectin antagonists showed rapid viral clearance in phase II trials, with no adverse effects and broad-spectrum potential. The company is pursuing both nutraceutical commercialization and drug approval, with additional pipeline assets in oxygen delivery for stroke.
Fiscal Year 2025
-
A clinical stage biotech is advancing three carbohydrate-based platforms targeting antivirals, stroke, and cancer metastasis, with a lead drug showing 100% viral reduction in trials. Top-line data is expected soon, and new partnerships are being pursued, including for immunotherapy and bird flu research.
-
Three AI-driven platform technologies were showcased, including a broad-spectrum antiviral with strong clinical results, an oxygenation molecule leveraging camel hemoglobin, and a cancer metastasis treatment. The company highlighted undervaluation, ongoing licensing, and upcoming clinical and funding milestones.
-
Three AI-driven platform technologies are advancing, including a broad-spectrum antiviral with strong clinical results and a scalable bird flu solution. Licensing and academic partnerships are central to growth, while recent financial restructuring has positioned the company for new funding and collaborations.
-
Three AI-driven platform technologies target viral infections, cancer, and oxygenation, with clinical data showing rapid viral clearance and promising cancer combination therapy results. The company is pursuing licensing, government partnerships, and rebranding as an inflammation-focused innovator.
-
Three AI-driven platform technologies target viral, oxygenation, and cancer indications, with clinical data showing 100% viral reduction and strong safety. Recent BARDA engagement highlighted funding opportunities and government interest, especially in broad-spectrum antivirals and oxygen carriers.